The extension to Opsona’s Series C round brings it to €36m following previous backing from firms including Novartis Venture Fund, Fountain Healthcare Partners, Sunstone Capital and Baxter Ventures.
Opsona said it would use the proceeds from the financing round to supplement funding of clinical trials for its lead drug in renal patients to evaluate its safety, efficacy and tolerability.
CEO Martin Welschof said, “I am delighted Omnes Capital is joining the exceptional Series C consortium of venture capital and corporate venture firms.
“The second closing of our Series C with Omnes Capital further validates the great medical and commercial potential of our drug candidate OPN-305.”
Paris-based Omnes was bought by UK secondaries investor Coller in March 2012, when Omnes spun out of France’s largest retail banking group Crédit Agricole.
An Omnes spokeswoman confirmed to AltAssets in January that the ownership was only ever designed to be a short-term arrangement, with Coller picking up all of Crédit Agricole’s stake to ease Omnes’ release from the bank.
She added that Omnes had plans to raise a new private equity fund, although did not reveal details.
The firm has recently invested €1m in Prodealcenter, a France-based online distribution of agricultural spare parts, €15m in the leveraged buyout of social housing renovation specialist Eratome Group and €4m in Italian biomass group Futuris.
Copyright © 2013 AltAssets